基本信息
浏览量:2
职业迁徙
个人简介
Research Interests
Hematopoietic and Endothelial Development
We are interested primarily in embryonic hematopoietic and endothelial development and in developmental lineal relationships between these two cell types.
In particular, we are interested in the role of the Vascular Endothelial Growth Factor (VEGF) receptor Flk-1 in the development of these two lineages. Flk-1 is known to mark the common embryonic progenitor of these two lineages, the hemangioblast, and plays a key role in the lineage determination events that underlie the origins of these cell types.
Ongoing work includes the use of gene targeting in embryonic stem (ES) cells to clarify the role of Flk-1 in embryonic hematopoiesis and endothelial development, and to facilitate the isolation and characterization of hemangioblasts.
Biology of CD109 in Hematopoietic Cells
We have recently cloned the human and murine cDNAs encoding the cell surface antigen CD109. This antigen marks very early hematopoietic stem cells with long-term reconstitution ability. And curiously, while it is not found on later progenitors or resting mature blood cells, CD109 reappears as a platelet and T cell activation antigen. Ongoing studies will elucidate the role(s) of CD109 in hematopoiesis, hemostasis and in cell-mediated immunity.
Gene Therapy of Acute Myeloblastic Leukemia (AML)
Using a murine model of AML, we are optimizing a gene therapy/tumour vaccination strategy for the control of minimal residual disease in patients with AML. Our goal is to use genetically engineered, patient-derived leukemia cell vaccines to enhance the graft-versus-leukemia effect seen after allogeneic bone marrow transplantation for AML. We anticipate that this strategy may be effective in the autologous setting as well, and therefore may provide a new therapeutic avenue to the majority of AML patients that are currently excluded from allogeneic transplantation. This strategy has been extremely successful to date in our animal model.
Related studies include the characterization of the developmental role of the blood coagulation system during embryonic and tumour angiogenesis, the isolation of novel genes expressed during embryonic hematopoiesis, and the development of a novel gene therapy approach to the treatment of hemophilia.
Hematopoietic and Endothelial Development
We are interested primarily in embryonic hematopoietic and endothelial development and in developmental lineal relationships between these two cell types.
In particular, we are interested in the role of the Vascular Endothelial Growth Factor (VEGF) receptor Flk-1 in the development of these two lineages. Flk-1 is known to mark the common embryonic progenitor of these two lineages, the hemangioblast, and plays a key role in the lineage determination events that underlie the origins of these cell types.
Ongoing work includes the use of gene targeting in embryonic stem (ES) cells to clarify the role of Flk-1 in embryonic hematopoiesis and endothelial development, and to facilitate the isolation and characterization of hemangioblasts.
Biology of CD109 in Hematopoietic Cells
We have recently cloned the human and murine cDNAs encoding the cell surface antigen CD109. This antigen marks very early hematopoietic stem cells with long-term reconstitution ability. And curiously, while it is not found on later progenitors or resting mature blood cells, CD109 reappears as a platelet and T cell activation antigen. Ongoing studies will elucidate the role(s) of CD109 in hematopoiesis, hemostasis and in cell-mediated immunity.
Gene Therapy of Acute Myeloblastic Leukemia (AML)
Using a murine model of AML, we are optimizing a gene therapy/tumour vaccination strategy for the control of minimal residual disease in patients with AML. Our goal is to use genetically engineered, patient-derived leukemia cell vaccines to enhance the graft-versus-leukemia effect seen after allogeneic bone marrow transplantation for AML. We anticipate that this strategy may be effective in the autologous setting as well, and therefore may provide a new therapeutic avenue to the majority of AML patients that are currently excluded from allogeneic transplantation. This strategy has been extremely successful to date in our animal model.
Related studies include the characterization of the developmental role of the blood coagulation system during embryonic and tumour angiogenesis, the isolation of novel genes expressed during embryonic hematopoiesis, and the development of a novel gene therapy approach to the treatment of hemophilia.
研究兴趣
论文共 267 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
crossref(2024)
Haematologicano. 2 (2024): 671-675
Akhil Rajendra Kurup,Vikas Gupta,Karen Yee,Dawn C Maze, Mark D Minden,Andre Schuh, Aaron D Schimmer,Aniket Bankar, Steven M Chan,Marta Beata Davidson,Guillaume Richard-Carpentier,Hassan Sibai
Clinical Lymphoma Myeloma & Leukemia (2024): S174-S174
EUROPEAN JOURNAL OF HAEMATOLOGYno. 5 (2024): 716-726
Leukemiano. 4 (2024): 912-913
加载更多
作者统计
#Papers: 271
#Citation: 18358
H-Index: 38
G-Index: 135
Sociability: 7
Diversity: 3
Activity: 77
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn